Brokerages expect that ABIOMED, Inc. (NASDAQ:ABMD) will post sales of $163.84 million for the current quarter, Zacks reports. Five analysts have made estimates for ABIOMED’s earnings, with estimates ranging from $163.50 million to $164.10 million. ABIOMED reported sales of $124.68 million in the same quarter last year, which would suggest a positive year over year growth rate of 31.4%. The business is expected to report its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that ABIOMED will report full-year sales of $163.84 million for the current year, with estimates ranging from $582.80 million to $586.05 million. For the next fiscal year, analysts expect that the firm will post sales of $745.13 million per share, with estimates ranging from $733.60 million to $757.16 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for ABIOMED.
ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. During the same period in the prior year, the business posted $0.34 earnings per share. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year.
ABIOMED (NASDAQ ABMD) traded up $4.48 during mid-day trading on Thursday, hitting $268.45. 367,055 shares of the stock traded hands, compared to its average volume of 466,230. The firm has a market capitalization of $11,870.00, a price-to-earnings ratio of 109.13, a PEG ratio of 3.59 and a beta of 0.36. ABIOMED has a twelve month low of $114.28 and a twelve month high of $274.00.
In related news, VP Andrew J. Greenfield sold 20,000 shares of ABIOMED stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.00% of the company’s stock.
Large investors have recently modified their holdings of the stock. Crow Point Partners LLC acquired a new stake in shares of ABIOMED in the 4th quarter valued at approximately $120,000. Cerebellum GP LLC acquired a new position in shares of ABIOMED in the fourth quarter worth approximately $127,000. Advisor Partners LLC acquired a new position in shares of ABIOMED in the fourth quarter worth approximately $209,000. SeaCrest Wealth Management LLC bought a new stake in shares of ABIOMED during the fourth quarter valued at approximately $183,000. Finally, BB&T Securities LLC purchased a new stake in ABIOMED during the 4th quarter worth about $219,000. Hedge funds and other institutional investors own 86.99% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3221956/zacks-brokerages-expect-abiomed-inc-abmd-will-post-quarterly-sales-of-163-84-million.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.